Visualizing lung function with positron emission tomography

Electrical impedance tomography applied to assess matching of pulmonary ventilation and perfusion in a porcine experimental model

INTRODUCTION

Electrical impedance tomography (EIT) can be used to measure impedance changes related to the thoracic content of air and blood. Few studies, however, have utilised EIT to make concurrent measurements of ventilation and perfusion. This experimental study was performed to investigate the feasibility of EIT to describe ventilation/perfusion (V/Q) matching after acute changes of pulmonary perfusion and aeration.

METHODS

Six mechanically ventilated, anaesthetised pigs in the supine position were studied at baseline, after inflation of a balloon in the inferior caval vein (Binfl) to reduce cardiac output and after an increased positive end-expiratory pressure (PEEP) of 20 cmH2O (PEEP20) to increase pulmonary aeration. EIT measurements were performed at the mid-thoracic level to measure the amplitude of impedance changes related to ventilation (ZV) and perfusion (ZQ), both globally and in four defined regions of interest (ROI) extending from the ventral to dorsal distance.

RESULTS

A largely parallel distribution of ZV and ZQ in all four ROIs during baseline conditions corresponded to a bell-shaped frequency distribution of ZV/ZQ ratios with only moderate scatter. Binfl and PEEP20 with unchanged tidal volumes significantly increased the mismatch of regional ZV and ZQ, the scatter of ZV/ZQ ratios and the heterogeneity of the ZV/ZQ frequency distribution. Significant positive and negative correlations were demonstrated between fractional alveolar dead space (r2 = 0.63 [regression coefficient]) and venous admixture (r2 = 0.48), respectively, and the global ZV/ZQ ratio.

CONCLUSIONS

EIT may be used to monitor the distribution of pulmonary ventilation and perfusion making detailed studies of V/Q matching possible.

Visualization of pulmonary inflammation using noninvasive fluorescence molecular imaging

The ability to visualize molecular processes and cellular regulators of complex pulmonary diseases such as asthma, chronic obstructive pulmonary disease (COPD), or adult respiratory distress syndrome (ARDS), would aid in the diagnosis, differentiation, therapy assessment and in small animal-based drug-discovery processes. Herein we report the application of normalized transillumination and fluorescence molecular tomography (FMT) for the noninvasive quantitative imaging of the mouse lung in vivo. We demonstrate the ability to visualize and quantitate pulmonary response in a murine model of LPS-induced airway inflammation. Twenty-four hours prior to imaging, BALB/c female mice were injected via tail vein with 2 nmol of a cathepsin-sensitive activatable fluorescent probe (excitation: 750 nm; emission: 780 nm) and 2 nmol of accompanying intravascular agent (excitation: 674 nm; emission: 694 nm). Six hours later, the mice were anesthetized with isoflurane and administered intranasal LPS in sterile 0.9% saline in 25 microl aliquots (one per nostril). Fluorescence molecular imaging revealed the in vivo profile of cysteine protease activation and vascular distribution within the lung typifying the inflammatory response to LPS insult. Results were correlated with standard in vitro laboratory tests (Western blot, bronchoalveolar lavage or BAL analysis, immunohistochemistry) and revealed good correlation with the underlying activity. We demonstrated the capacity of fluorescence tomography to noninvasively and longitudinally characterize physiological, cellular, and subcellular processes associated with inflammatory disease burden in the lung. The data presented herein serve to further evince fluorescence molecular imaging as a technology highly appropriate for the biomedical laboratory.

In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium

Nanoparticles (NPs) targeting the intercellular adhesion molecule 1 (ICAM-1) hold promise as a mean of delivering therapeutics to the pulmonary endothelium in patients with acute and chronic respiratory diseases. As these new materials become available, strategies are needed to understand their behavior in vivo. We have evaluated the use of (64)Cu and PET to noninvasively image the lung uptake and distribution of NPs coated with an anti-ICAM antibody.

METHODS

Model fluorescent NPs were coated with a mixture of an anti-ICAM antibody (or nonspecific IgG) and (64)Cu-DOTA-IgG (where DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). Biodistribution and small-animal PET and CT studies were performed in healthy mice and in mice pretreated with lipopolysaccharides (LPSs). Metabolism studies were also performed to evaluate the stability of (64)Cu-labeled NPs in lungs in vivo.

RESULTS

The lungs of mice administered anti-ICAM NPs labeled with (64)Cu were clearly imaged by small-animal PET 1, 4, and 24 h after administration. Both biodistribution and small-animal imaging showed a 3- to 4-fold higher uptake in the lungs of mice injected with ICAM-targeted NPs relative to that of the control group. Lung uptake was further enhanced by pretreating the mice with LPS, presumably because of ICAM-1 upregulation. However, an approximately 2-fold decrease in lung signal was observed in each experimental group over 24 h. Metabolism studies in lung tissues harvested from mice injected with (64)Cu-labeled anti-ICAM NPs showed considerable release of a small (64)Cu-radiometabolite from the NPs beginning as early as 1 h after injection. A decrease in lung fluorescence was also observed, most likely reflecting partial release of NPs from the lungs in vivo.

CONCLUSION

The use of small-animal PET to track (64)Cu-labeled nanostructures in vivo shows potential as a strategy for the preclinical screening of new NP drug delivery agents targeting the lung endothelium and other tissues. Future design optimization to prolong the stability of the radiolabel in vivo will further improve this promising approach.

How to monitor lung recruitment in patients with acute lung injury

PURPOSE OF REVIEW

Bedside assessment of lung recruitment is critical for setting mechanical ventilation during acute respiratory distress syndrome. We review recent findings on this topic and attempt to provide a clinical approach to estimating lung recruitment.

RECENT FINDINGS

Because of intrinsic limitations in considering single parameters of gas exchange as tools to estimate lung recruitment, investigators have combined different respiratory variables, including respiratory mechanics, to enhance the likelihood of predicting lung recruitment. Confusions on interpreting the physiologic rationale of gas-exchange variations as associated with lung recruitment are still widespread. Techniques of lung imaging, in particular computed-tomography scanning, are still the most applied for reference measurement. Dynamic computed-tomography scanning may allow continuous monitoring of the effects of mechanical ventilation on lung parenchyma. Among the new techniques proposed, electric impedance and positron emission tomography are the most promising. Despite progress, computed-tomography scanning still represents the best technique to measure lung recruitment in clinical practice.

SUMMARY

Two approaches should be considered to estimate lung recruitment: the use of computed-tomography scanning and indices combining different respiratory variables. Future studies, especially on lung-perfusion distribution, are warranted to improve our knowledge of the pathophysiology of lung recruitment.

The opportunities and challenges of developing imaging biomarkers to study lung function and disease

Recent advances in imaging offer exciting opportunities to develop and validate lung-specific biomarkers as valuable adjuncts to diagnosis, tests of treatment efficacy, and/or treatment monitoring. State-of-the-art structural, functional, and molecular imaging methods allow the lungs to be visualized noninvasively in vivo at submillimeter and subsecond spatial and temporal scales. However, the development and validation of imaging biomarkers present some special challenges, including the following: equipment evaluation, procedure standardization, data regarding reproducibility and replication, interrater variability, the production and measurement of reference standards, sensitivity to interventions or disease progression, intersubject variance, choice of image reconstruction and segmentation algorithms, automated versus observer-dependent image analysis, data acquisition during conditions of standardized lung volume, whether a reliable association can be demonstrated between the imaging biomarker and a clinical endpoint, and whether its use will have a favorable cost-effective impact on drug development or disease management. Establishing such performance characteristics, especially for single investigators at single institutions, can be daunting if not impossible for costly biomarkers such as imaging. Therefore, to take full advantage of the opportunities presented by state-of-the-art imaging methods, new approaches to analytic and clinical validation must be developed in collaboration with industry, foundation, and federal funding agencies.